Success Metrics

Clinical Success Rate
93.2%

Based on 41 completed trials

Completion Rate
93%(41/44)
Active Trials
17(19%)
Results Posted
24%(10 trials)
Terminated
3(3%)

Phase Distribution

Ph phase_4
2
2%
Ph phase_1
7
8%
Ph not_applicable
52
57%
Ph phase_2
6
7%
Ph phase_3
5
5%
Ph early_phase_1
1
1%

Phase Distribution

8

Early Stage

6

Mid Stage

7

Late Stage

Phase Distribution73 total trials
Early Phase 1First-in-human
1(1.4%)
Phase 1Safety & dosage
7(9.6%)
Phase 2Efficacy & side effects
6(8.2%)
Phase 3Large-scale testing
5(6.8%)
Phase 4Post-market surveillance
2(2.7%)
N/ANon-phased studies
52(71.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.2%

41 of 47 finished

Non-Completion Rate

12.8%

6 ended early

Currently Active

17

trials recruiting

Total Trials

91

all time

Status Distribution
Active(24)
Completed(41)
Terminated(6)
Other(20)

Detailed Status

Completed41
unknown20
Recruiting14
Not yet recruiting6
Withdrawn3
Active, not recruiting3

Development Timeline

Analytics

Development Status

Total Trials
91
Active
17
Success Rate
93.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.4%)
Phase 17 (9.6%)
Phase 26 (8.2%)
Phase 35 (6.8%)
Phase 42 (2.7%)
N/A52 (71.2%)

Trials by Status

withdrawn33%
active_not_recruiting33%
recruiting1415%
completed4145%
enrolling_by_invitation11%
terminated33%
unknown2022%
not_yet_recruiting67%

Recent Activity

Clinical Trials (91)

Showing 20 of 91 trialsScroll for more
NCT07710300Not Applicable

Randomized Controlled Trial Testing a Training Program About Section 504 of the Rehabilitation Act

Recruiting
NCT05148286Phase 4

Albumin and Crystalloid Administration in Septic Shock

Recruiting
NCT07698119Not Applicable

A Trial of the Arctx Cool Catheter in Acute Pancreatitis

Not Yet Recruiting
NCT03841734Phase 3

Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO

Completed
NCT07637487Not Applicable

Tocotrienol Supplementa as A Senolytic Agent in Middle-aged Adults

Recruiting
NCT07176234Not Applicable

The LEADS Trial (Linking Exericise for Advancing Daily Stress Management)

Enrolling By Invitation
NCT05196503Phase 3

Efficacy of an Intraoperative Periradicular Application of Platelet Rich Fibrin (PRF) on the Intensity of Residual Post-surgical Neuropathic Pain After a Surgery for Disc Herniation

Recruiting
NCT07542717Phase 1

ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer

Not Yet Recruiting
NCT06782464Not Applicable

Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment

Recruiting
NCT06579209Not Applicable

NAD+ Oral Supplement Pilot Intervention in Adult Females

Completed
NCT04571008Not Applicable

Effect of NMN Supplementation on Organ System Biology

Completed
NCT07376031Not Applicable

Cervical Thermal Ablation to Treat Persistent HPV Infection

Completed
NCT07371858Not Applicable

The Effect of Home-Based Exercise on Chronic Kidney Disease Patients

Completed
NCT07322211Not Applicable

A Study to Evaluate the Clinical Performance and Safety of UNICON Silicone Hydrogel Daily Disposable Soft Contact Lenses

Recruiting
NCT07339553Phase 2

Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.

Not Yet Recruiting
NCT07323693Not Applicable

Clinical Efficacy of Using Bioactive Desensitizer Gel

Completed
NCT02039752

Asan Multivessel Registry

Recruiting
NCT05689502Not Applicable

intenSive UpPer Extremity Recovery Program for Chronic Stroke (SUPER)

Active Not Recruiting
NCT07239622Phase 2

Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma

Not Yet Recruiting
NCT02392455

VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)

Completed

Drug Details

Intervention Type
OTHER
Total Trials
91